Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome - PubMed (original) (raw)

Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome

B M Lodde et al. Ann Rheum Dis. 2006 Feb.

Abstract

Background: Sjögren's syndrome (SS), an autoimmune exocrinopathy mainly affecting lachrymal and salivary glands, results in ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). The aetiology and pathogenesis are largely unknown; currently, only palliative treatment is available.

Objective: To determine whether gene transfer of vasoactive intestinal peptide (VIP), based on its immunomodulatory properties, might be useful in the management of SS.

Methods: A recombinant serotype 2 adeno-associated virus encoding the human VIP transgene (rAAV2hVIP) was constructed and its efficacy tested in the female non-obese diabetic (NOD) mouse model for SS after retrograde instillation in submandibular glands (SMGs). 10(10) particles/gland of rAAV2hVIP or rAAV2LacZ (encoding beta-galactosidase; control vector) were administered at 8 weeks of age (before sialadenitis onset). Salivary flow rates were determined before vector delivery and at time of death (16 weeks). After death, saliva, serum, and SMGs were harvested. Salivary output, inflammatory infiltrates (focus scores), VIP protein expression, cytokine profile, and serum anti-VIP antibodies were analysed.

Results: rAAV2hVIP significantly improved the salivary flow, increased SMG and serum expression of VIP, and reduced SMG cytokines interleukin (IL) 2, IL10, IL12 (p70), and tumour necrosis factor alpha, and serum RANTES, compared with the control vector. No difference in focus scores or apoptotic rates was found; neutralising antibodies were not detected.

Conclusions: Local delivery of rAAV2hVIP can have disease modifying and immunosuppressive effects in SMGs of the NOD mouse model of SS. The new strategy of employing VIP prophylactically may be useful for both understanding and managing the salivary component of SS.

PubMed Disclaimer

Figures

Similar articles

• Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.
  Hauk V, Calafat M, Larocca L, Fraccaroli L, Grasso E, Ramhorst R, Leirós CP. Hauk V, et al. Clin Exp Immunol. 2011 Dec;166(3):309-16. doi: 10.1111/j.1365-2249.2011.04478.x. Clin Exp Immunol. 2011. PMID: 22059987 Free PMC article.
• NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.
  Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, Cotrim AP, Kriete M, Tak PP, Baum BJ. Lodde BM, et al. Oral Dis. 2006 Nov;12(6):566-72. doi: 10.1111/j.1601-0825.2006.01241.x. Oral Dis. 2006. PMID: 17054769
• Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.
  Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ. Kok MR, et al. Hum Gene Ther. 2003 Nov 20;14(17):1605-18. doi: 10.1089/104303403322542257. Hum Gene Ther. 2003. PMID: 14633403
• Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.
  Kok MR, Baum BJ, Tak PP, Pillemer SR. Kok MR, et al. Ann Rheum Dis. 2003 Nov;62(11):1038-46. doi: 10.1136/ard.62.11.1038. Ann Rheum Dis. 2003. PMID: 14583564 Free PMC article. Review.
• Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.
  Lodde BM, Baum BJ, Tak PP, Illei G. Lodde BM, et al. Ann Rheum Dis. 2006 Nov;65(11):1406-13. doi: 10.1136/ard.2006.052761. Epub 2006 Jul 31. Ann Rheum Dis. 2006. PMID: 16880196 Free PMC article. Review.

Cited by

• Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis.
  Hauk V, Fraccaroli L, Grasso E, Eimon A, Ramhorst R, Hubscher O, Pérez Leirós C. Hauk V, et al. Clin Exp Immunol. 2014 Sep;177(3):662-70. doi: 10.1111/cei.12378. Clin Exp Immunol. 2014. PMID: 24827637 Free PMC article.
• IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer.
  Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. Nguyen CQ, et al. Lab Invest. 2011 Jan;91(1):54-62. doi: 10.1038/labinvest.2010.164. Epub 2010 Sep 20. Lab Invest. 2011. PMID: 20856230 Free PMC article.
• VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction.
  Carrión M, Juarranz Y, Seoane IV, Martínez C, González-Álvaro I, Pablos JL, Gutiérrez-Cañas I, Gomariz RP. Carrión M, et al. J Mol Neurosci. 2014 Jan;52(1):10-7. doi: 10.1007/s12031-013-0177-3. Epub 2013 Nov 20. J Mol Neurosci. 2014. PMID: 24254222
• Protective Effect of Zengye Decoction () on Submandibular Glands in Nonobese Diabetic Mice.
  Li CY, Wu SL, Sun LX, Yan TT, Wang Y. Li CY, et al. Chin J Integr Med. 2019 Jan;25(1):45-50. doi: 10.1007/s11655-014-1981-5. Epub 2014 Sep 24. Chin J Integr Med. 2019. PMID: 25253552
• Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.
  Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, Delgado M. Pozo D, et al. Peptides. 2007 Sep;28(9):1833-46. doi: 10.1016/j.peptides.2007.04.008. Epub 2007 Apr 20. Peptides. 2007. PMID: 17521775 Free PMC article. Review.

References

1. 1. Jonsson R, Hagan H‐J, Gordon T. Sjögren's syndrome. In: Koopman WJ, ed. Arthritis and allied conditions ‐ a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins, February20011736–1759.
2. 1. Cha S, Peck A B, Humphreys‐Beher M G. Progress in understanding autoimmune exocrinopathy using the non‐obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002135–16. - PubMed
3. 1. Borchers A T, Naguwa S M, Keen C L, Gershwin M E. Immunopathogenesis of Sjögren's syndrome. Clin Rev Allergy Immunol 20032589–104. - PubMed
4. 1. Said S I. Vasoactive intestinal peptide. J Endocrinol Invest 19869191–200. - PubMed
5. 1. Gozes I, Furman S. VIP and drug design. Curr Pharm Des 20039483–494. - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Medical

  • MedlinePlus Health Information